Pantop%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. * In combination with antibiotics for the eradication of *Helicobacter pylori* infection. ## Adult Dosing * **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. For patients with erosive esophagitis that has recurred, dosage may be increased to 80 mg once daily. * **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses can be increased as needed. Doses greater than 80 mg daily should be divided and given every 12 hours. * ***H. pylori* Eradication (in combination therapy):** 40 mg orally twice daily for 7 to 14 days. ## Pediatric Dosing * **GERD and Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks. * *Limited data available for pediatric use outside of GERD and erosive esophagitis.* ## Dose Adjustments No dose adjustment is generally necessary for patients with hepatic impairment. However, for patients with severe hepatic impairment, a maximum daily dose of 20 mg orally or 40 mg intravenously is recommended. No dose adjustment is needed for renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole, any of its components, or other substituted benzimidazoles. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, dizziness, abdominal pain, and flatulence. Long-term use may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, and vitamin B12 deficiency. ## Key Drug Interactions * Drugs requiring gastric acid for absorption (e.g., certain antifungals like ketoconazole, itraconazole; certain HIV protease inhibitors): Pantoprazole can decrease absorption. * Methotrexate: PPIs may increase methotrexate levels, potentially leading to toxicity. * CYP2C19 substrates: Pantoprazole is a moderate inhibitor of CYP2C19. ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures). * Monitor for bone mineral density in patients at risk for osteoporosis. * Monitor for signs of vitamin B12 deficiency with prolonged use. * Assess for effectiveness of treatment and symptom relief. ## Clinical Pearls * Administer orally before a meal, preferably breakfast. * For IV administration, reconstitute and infuse over 15 minutes. * Parenteral administration may be switched to oral therapy when clinically appropriate. * Do not crush or chew delayed-release pantoprazole tablets. * If using pantoprazole for *H. pylori* eradication, ensure adherence to the full antibiotic regimen. *** **Disclaimer:** This information is intended for clinical use and is not exhaustive. Always consult the most current prescribing information and relevant guidelines for complete details and to ensure patient safety.